Victory Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$51M Buy
156,294
+118,645
+315% +$38.7M 0.03% 540
2025
Q1
$10.2M Sell
37,649
-2,148
-5% -$580K 0.01% 1033
2024
Q4
$9.36M Sell
39,797
-3,112
-7% -$732K 0.01% 1104
2024
Q3
$11.8M Buy
42,909
+4,229
+11% +$1.16M 0.01% 1048
2024
Q2
$9.4M Sell
38,680
-724
-2% -$176K 0.01% 1100
2024
Q1
$5.89M Sell
39,404
-6,334
-14% -$947K 0.01% 1198
2023
Q4
$8.75M Sell
45,738
-13,149
-22% -$2.52M 0.01% 1101
2023
Q3
$10.4M Sell
58,887
-1,606
-3% -$284K 0.01% 999
2023
Q2
$11.5M Sell
60,493
-377
-0.6% -$71.6K 0.01% 982
2023
Q1
$12.2M Buy
60,870
+738
+1% +$148K 0.01% 963
2022
Q4
$14.3M Buy
60,132
+1,045
+2% +$248K 0.02% 901
2022
Q3
$11.8M Buy
59,087
+7,822
+15% +$1.57M 0.01% 1011
2022
Q2
$7.48M Sell
51,265
-220
-0.4% -$32.1K 0.01% 1153
2022
Q1
$6.87M Sell
51,485
-4,877
-9% -$651K 0.01% 1226
2021
Q4
$9.56M Buy
56,362
+484
+0.9% +$82.1K 0.01% 1141
2021
Q3
$10.6M Buy
55,878
+14,756
+36% +$2.79M 0.01% 1090
2021
Q2
$6.97M Sell
41,122
-16,922
-29% -$2.87M 0.01% 1232
2021
Q1
$8.2M Buy
58,044
+7,080
+14% +$1,000K 0.01% 1197
2020
Q4
$6.62M Buy
50,964
+6,151
+14% +$799K 0.01% 1176
2020
Q3
$6.53M Buy
44,813
+6,726
+18% +$979K 0.01% 1140
2020
Q2
$5.64M Sell
38,087
-43,947
-54% -$6.51M 0.01% 1135
2020
Q1
$8.93M Buy
82,034
+65,561
+398% +$7.14M 0.01% 1117
2019
Q4
$1.9M Buy
16,473
+1,127
+7% +$130K ﹤0.01% 1528
2019
Q3
$1.23M Buy
+15,346
New +$1.23M ﹤0.01% 1645
2018
Q2
Sell
-15,555
Closed -$1.85M 1821
2018
Q1
$1.85M Sell
15,555
-4,380
-22% -$522K ﹤0.01% 1088
2017
Q4
$2.53M Sell
19,935
-3,240
-14% -$412K 0.01% 961
2017
Q3
$2.72M Sell
23,175
-2,850
-11% -$335K 0.01% 903
2017
Q2
$2.08M Buy
26,025
+1,210
+5% +$96.5K ﹤0.01% 939
2017
Q1
$1.27M Buy
24,815
+4,725
+24% +$242K ﹤0.01% 1077
2016
Q4
$752K Buy
+20,090
New +$752K ﹤0.01% 1197